Praxis Precision Medicines, Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q4 2025). Net income: −$339M, trailing twelve months to Q2 2026. Free cash flow: −$305M, trailing twelve months to Q2 2026. EPS: −$12.94, trailing twelve months to Q2 2026.

PRAXPraxis Precision Medicines, Inc.

Healthcare

$259.82+515% 1Y

$259.82

$48.3352 weeks$386.42

PRAX as reported

Praxis Precision Medicines, Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied

Net income: −$339M
Net income · +35% year on year · trailing twelve months to Q2 2026
Free cash flow: −$305M
Free cash flow · +60% year on year · trailing twelve months to Q2 2026
EPS: −$12.94
EPS · +4.8% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PRAX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q4 2025
Net income	−$339M	+35%	Q2 2026
EPS	−$12.94	+4.8%	Q2 2026
Operating margin	−9974%	n/a	Q4 2024 · 6 quarters behind
Net margin	−9076%	n/a	Q4 2024 · 6 quarters behind
ROE	−41%	n/a	Q2 2026
ROA	−37%	n/a	Q2 2026
Free cash flow	−$305M	+60%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.